AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10201459
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg twice daily (maintenance)
Trial: 8519715
Drug: Fentanyl 15
RxNorm normalized name: fentaNYL 150 mcg/30 mL-D5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 15 micrograms with 80 mg hyperbaric lidocaine
Trial: 8519715
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline with 80 mg hyperbaric lidocaine
Trial: 2167110
Drug: Transcatheter arterial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter arterial embolization (TAE) using iodized oil (Lipiodol) mixed with anticancer agent (ACA)
Trial: 2167110
Drug: Hepatic artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic artery infusion (HAI) of anticancer agent (ACA)
Trial: 2167110
Drug: Oral chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chemotherapy following TAE or HAI
Trial: 206214
Drug: Surgical excision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical excision of the tumor, chemotherapy, and radiation therapy as per study protocol
Trial: 19666698
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with T4 (50 microg) and T3 (20 microg) for 12 weeks
Trial: 19666698
Drug: T4 monotherapy
RxNorm normalized name: T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: T4 monotherapy for 12 weeks
Trial: 1852141
Drug: Nimesulide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide (100 mg bid orally)
Trial: 7193603
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive 20/250 (EE/NG ratio 0.08)
Trial: 7193603
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive 30/250 (EE/NG ratio 0.12)
Trial: 7193603
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive 30/150 (EE/NG ratio 0.20)
Trial: 7193603
Drug: Three-phase drug
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-phase drug (EE/NG ratio 0.35)
Trial: 30702853
Drug: Real world
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real world data (RWD) studies on drug repurposing
Trial: 17324009
Drug: Plerixafor plus
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plerixafor plus G-CSF
Trial: 21392395
Drug: Oral diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diet and EN if necessary after 72 hours after hospital admission
Trial: 19145396
Drug: Ibandronate (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate (150 mg, once-monthly)
Trial: 11490418
Drug: Doxicyclin 200
RxNorm normalized name: doxycycline hyclate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxicyclin 200 mg/day with nistatine for three weeks with 3‐week interval between the courses and bifidum‐bacterin administration between the courses and after the treatment
Trial: 11490418
Drug: Biseptol 1920
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biseptol 1920 mg for 3 weeks then 960 mg 10 days a month
Trial: 11490418
Drug: No antibacterial
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibacterial drugs
Trial: 9990420
Drug: Adapalene 0.1%
RxNorm normalized name: ADAPALENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1% solution
Trial: 9990420
Drug: Adapalene 0.1%
RxNorm normalized name: ADAPALENE 0.1% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene 0.1% solution and Tretinoin 0.025% gel
Trial: 24533510
Drug: Unopposed estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unopposed estrogen (estradiol valerate: 2 mg for 2 years)
Trial: 23866906
Drug: Electroacupuncture (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (30 minutes with a mixed current of 2 Hz/120 Hz at 80% of bearable intensity) at 12 standard acupuncture points, twice per week for eight weeks (total of 16 sessions)
Trial: 23866906
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (no electroacupuncture treatment)
Trial: 20593240
Drug: Rofecoxib (selective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (selective COX-2 inhibitor)
Trial: 11168669
Drug: 0.3% gentian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% gentian violet applied twice a day for nasal lesions (9 cases)
Trial: 8779402
Drug: 8 ml
RxNorm normalized name: ethanol 0.8 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 ml bupivacaine 0.25% + 0.1 mg fentanyl (B + F group)
Trial: 8779402
Drug: 8 ml
RxNorm normalized name: ethanol 0.8 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 ml bupivacaine 0.25% + 2 ml saline (BUP group)
Trial: 29601997
Drug: Carbohydrate (CHO)
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (CHO) restricted diet (<25:>50:25% daily calories from CHO: fat: protein)
Trial: 29601997
Drug: Fat restricted
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fat restricted diet (55:20:25% daily calories from CHO: fat: protein)
Trial: 24641783
Drug: Powered rotating-oscillating
RxNorm normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Powered rotating-oscillating toothbrush with repeated oral hygiene instructions (OHI) and motivation (Group E1)
Trial: 24641783
Drug: Manual toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual toothbrush with repeated oral hygiene instructions (OHI) and motivation (Group M1)
Trial: 24641783
Drug: Powered rotating-oscillating
RxNorm normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Powered rotating-oscillating toothbrush without repeated oral hygiene instructions (OHI) and motivation (Group E2)
Trial: 24641783
Drug: Manual toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual toothbrush without repeated oral hygiene instructions (OHI) and motivation (Group M2)
Trial: 18284435
Drug: Troglitazone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (200 mg/day) for 12 weeks
Trial: 10459816
Drug: Isepamicin 25
RxNorm normalized name: isepamicin
DrugBank: Isepamicin (DB13540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isepamicin 25 mg/kg on the first day followed by 15 mg/kg od for 4 days
Trial: 10459816
Drug: Isepamicin 15
RxNorm normalized name: isepamicin
DrugBank: Isepamicin (DB13540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isepamicin 15 mg/kg od for 5 days
Trial: 10459816
Drug: Isepamicin 15
RxNorm normalized name: isepamicin
DrugBank: Isepamicin (DB13540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isepamicin 15 mg/kg od for 10 days
Trial: 10459816
Drug: Isepamicin dosing
RxNorm normalized name: isepamicin
DrugBank: Isepamicin (DB13540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isepamicin dosing regimens
Trial: 7541236
Drug: Ibuprofen (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (1200 mg day‐1 for 7 days)
Trial: 525840
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of a parasympatholytic agent
Trial: 24313873
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg (intravenous and oral) administered on two occasions
Trial: 17427836
Drug: Statin therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy, specific dosage and duration not available
Trial: 15899725
Drug: Tacrolimus capsules
RxNorm normalized name: Tacrolimus Capsules
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus capsules with sirolimus
Trial: 11475731
Drug: Cassia angustifolia
RxNorm normalized name: Cassia angustifolia leaf
DrugBank: Senna leaf (DB15889)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cassia angustifolia extract (CAE) enema administration
Trial: 155292
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ipratropium bromide (IPTB) and disodium cromoglycate (DSCG)
Trial: 155292
Drug: Fenoterol (beta-adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (beta-adrenergic agonist)
Trial: 26520171
Drug: Topical polyvinyl
RxNorm normalized name: Polyvinyl Alcohol
DrugBank: Polyvinyl alcohol (DB11060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical polyvinyl alcohol (PA)
Trial: 22488578
Drug: ICG-augmented diode
RxNorm normalized name: ICG-136
DrugBank: ICG-136 (DB17343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICG-augmented diode laser therapy (808 nm) with ICG (2 mg/kg body weight) and diode laser pulses (50-110 J/cm²)
Trial: 22488578
Drug: Diode laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diode laser therapy without ICG
Trial: 11054990
Drug: Vitamin C;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C; specific dosage and duration not mentioned
Trial: 8790030
Drug: Special Intervention
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special Intervention (SI) - dietary recommendations, antihypertensive drugs, counseling for smoking cessation
Trial: 6360750
Drug: Fenoprofen 600
RxNorm normalized name: fenoprofen 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoprofen 600 mg, four times daily
Trial: 6360750
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg, four times daily
Trial: 6360750
Drug: Fenoprofen 600
RxNorm normalized name: fenoprofen 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoprofen 600 mg, four times daily (combined data from Weeks 1 and 2)
Trial: 6360750
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg, four times daily (combined data from Weeks 1 and 2)
Trial: 26654956
Drug: Client-centred activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Client-centred activities in daily living intervention (CADL)
Trial: 25972101
Drug: Cefazolin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (single intravenous dose)
Trial: 23217479
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of pre-operative antibiotics (cefuroxime sodium and metronidazole)
Trial: 23217479
Drug: Postoperative antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative antibiotics (same antibiotics as group A)
Trial: 23217479
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of pre-operative antibiotics (cefuroxime and metronidazole)
Trial: 20652627
Drug: Dronedarone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronedarone (400 mg or 800 mg once daily or 600 mg twice daily)
Trial: 18520806
Drug: Weekly intravenous
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly intravenous cetuximab (initial dose 400mg/m2; maintenance dose 250 mg/m2) with concomitant radiotherapy (64Gy/32 fractions/45 days)
Trial: 2246493
Drug: Cimetidine 800
RxNorm normalized name: cimetidine 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 800 mg twice daily
Trial: 6286734
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of enalapril (5 or 10 mg) and hydrochlorothiazide (50 mg)
Trial: 6286734
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 or 10 mg)
Trial: 25130995
Drug: STAS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STAS plus zoledronic acid (4 mg every 3 months for 18 months, intravenously)
Trial: 22895556
Drug: Low-dose decitabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose decitabine plus aclacinomycin/cytarabine (DAA)
Trial: 16143730
Drug: Ketamine (0.23
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.23 mg/kg IV followed by 0.5 mg/kg infusion)
Trial: 16143730
Drug: Amphetamine (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine (0.25 mg/kg infusion)
Trial: 12355581
Drug: Glucophage (Lipha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucophage (Lipha Pharmaceutical Industries, France)
Trial: 10418540
Drug: Sertraline hydrochloride
RxNorm normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline hydrochloride 50 mg (cycle 1)
Trial: 10418540
Drug: Sertraline hydrochloride
RxNorm normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline hydrochloride 100 mg (cycle 2)
Trial: 2153765
Drug: CAV-HEM chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAV-HEM chemotherapy
Trial: 2153765
Drug: CAV chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAV chemotherapy
Trial: 2153765
Drug: CAV maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAV maintenance therapy
Trial: 2153765
Drug: CAV-HEM with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAV-HEM with no maintenance therapy
Trial: 28737452
Drug: Cognitive rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive rehabilitation program (1-hour sessions weekly for 8 weeks)
Trial: 28737452
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (relaxation techniques weekly)
Trial: 25015615
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose (0.4 mg tamsulosin)
Trial: 25015615
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose (0.4 mg tamsulosin + 10 mg alfuzosin)
Trial: 22441634
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (MFNS) 200μg once daily
Trial: 31821491
Drug: Oral education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral education
Trial: 18671885
Drug: Oxpentifylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxpentifylline (400 mg daily)
Trial: 18671885
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 tablet daily)
Trial: 19753737
Drug: Dexpanthenol-containing cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexpanthenol-containing cream
Trial: 8529437
Drug: Twice-a-day combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-a-day combined administration
Trial: 2028709
Drug: Cytidine 5'-diphosphocholine
RxNorm normalized name: Cytidine 5'-diphosphocholine
DrugBank: Citicoline (DB12153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytidine 5'-diphosphocholine (2 g iv infusion)
Trial: 6987042
Drug: Cephradine given
RxNorm normalized name: Cephradine
DrugBank: Cefradine (DB01333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cephradine given twice daily (70 patients)
Trial: 6987042
Drug: Cephradine given
RxNorm normalized name: Cephradine
DrugBank: Cefradine (DB01333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cephradine given four times daily (61 patients)
Trial: 27883295
Drug: ABCC5 rs939339A>G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABCC5 rs939339A>G
Trial: 25125580
Drug: PF‐05105679 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐05105679 (600 mg)
Trial: 25125580
Drug: PF‐05105679 (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐05105679 (900 mg)
Trial: 25125580
Drug: Oxycodone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (20 mg)
Trial: 18928997
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (vitamin C 1000 mg and vitamin E 400 IU)
Trial: 2491361
Drug: Cimetidine, 800
RxNorm normalized name: Cimetidine, 800 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine, 800 mg once daily
Trial: 21550950
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir at 50% of intravenous basal insulin requirements
Trial: 21550950
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir at 65% of intravenous basal insulin requirements
Trial: 21550950
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir at 80% of intravenous basal insulin requirements
Trial: 18807247
Drug: Delta(9)‐THC (0.0286
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delta(9)‐THC (0.0286 mg/kg)
Trial: 11298545
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (ALA-PDT)
Trial: 30336808
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of granisetron (1 mg tablet, twice daily every 12 hours for 5 days)
Trial: 30336808
Drug: Transdermal delivery
RxNorm normalized name: nitroglycerin 5 mg in 1 d TRANSDERMAL PATCH [Nitroglycerin Transdermal Delivery System]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal delivery of granisetron (34.3 mg/52 cm2 patch for 6 days)
Trial: 21660397
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (zinc acetate syrup)
Trial: 21660397
Drug: Placebo (vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vitamin B-complex syrup)
Trial: 17213598
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 7.5 mg bupivacaine + 5 microg sufentanil + 10% glucose
Trial: 17213598
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 7.5 mg bupivacaine + 7.5 microg sufentanil + 10% glucose
Trial: 17213598
Drug: Group C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C: 15 mg bupivacaine + 10% glucose
Trial: 11818299
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (non-drug-related television program)
Trial: 10430716
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (20 ppm delivered during inspiration)
Trial: 10430716
Drug: Norepinephrine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine + Inhaled NO
Trial: 10430716
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate + Inhaled NO
Trial: 10430716
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate + Norepinephrine + Inhaled NO
Trial: 2144835
Drug: Nicotinamide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide (100 mg/year of age up to a maximum of 1.5 g/day)
Trial: 6996121
Drug: Luteinizing hormone‐releasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luteinizing hormone‐releasing hormone (LH‐RH) 500 micrograms 8‐hourly
Trial: 6361311
Drug: Long-acting cephalexin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting cephalexin granules (L-CEX)
Trial: 30286416
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg over 45 minutes)
Trial: 27431306
Drug: Daily nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily nasal saline irrigation supported by a demonstration video
Trial: 27431306
Drug: Daily steam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily steam inhalation
Trial: 27431306
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with both interventions
Trial: 22040532
Drug: SABA purchased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SABA purchased with prescription
Trial: 22040532
Drug: SABA purchased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SABA purchased without prescription
Trial: 22040532
Drug: Anti‐inflammatory asthma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti‐inflammatory asthma medication
Trial: 16285996
Drug: Triflusal 300
RxNorm normalized name: triflusal 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triflusal 300 mg/day